Walgreens and DalCor Pharmaceuticals are seeking volunteers.

Are you 45 years of age or older, and have you been hospitalized for a heart attack within the past 3 months?

Consider joining the Dal-GenE-2 clinical research study to evaluate the effects of dalcetrapib, an investigational drug, on cardiovascular risk in people who were recently hospitalized for a heart attack. 

Click here to see if you qualify for the study!

Why is the Dal-GenE-2 study important?

Heart disease affects many people, killing more Americans than any other condition, and is influenced by various factors, such as age, genetics, and lifestyle. For Black Americans, the risk of heart disease is even higher as they are 30% more likely to die of heart disease than non-Hispanic white Americans¹. This study is focused on a certain genotype that is found in people of all races and ethnicities, but somewhat higher in non-white individuals. So, diversity in study participants is necessary to ensure that we understand how this treatment works for different people.

Previous studies with this drug have shown a potential reduction in heart attacks in patients with the specific genotype that will be studied in this trial. That’s why DalCor Pharmaceutical is studying this new drug that could potentially offer a better way to prevent heart issues.

Your participation could contribute to advancing our understanding and improving treatment options for this widespread and life-threatening condition.

¹ U.S. Department of Health & Human Services

Study Overview

Eligibility Criteria

You may be eligible for this study if you:

  • Are 45 years of age or older  

  • Were recently hospitalized for acute coronary syndrome (severe and sudden heart condition, including heart attacks) within the past 3 months

There will be other study requirements that the study team will discuss with you, including genetic testing to ensure you are a good fit. 

Taking part in this study involves:

  • Learning about the details of the study and giving your consent to take part

  • Having study visits about every 3 months after the initial visit

  • Taking a once-daily medication with your largest meal

If you qualify and choose to join Dal-GenE-2 clinical research study, you will be randomly assigned to a study group in which you will receive either the investigational drug or a placebo. Throughout the study, you will be able to continue taking your current medications.

Whether you receive the investigational drug, dalcetrapib, or placebo will be determined randomly (by chance, like flipping a coin).

This study is double-blind, meaning neither you nor the study doctor will know which medication you received until all patients complete the study and the data are analyzed.


Frequently asked questions

  • Clinical research is the process of developing medicines or therapies to possibly prevent, treat, or help with diseases. Before a medicine can become available, it must be tested in a series of clinical studies to understand if it is safe and effective. With the help of clinical study participants, researchers are able to find out if and how potential new medicines work.

  • Participation in the Dal-GenE-2 study requires written informed consent for assessments, including genetic testing. You will need to visit the study clinic for screening and randomization. After randomization, you will have virtual visits (where applicable) or clinic visits every 3 months for assessments.

  • An investigational drug is the medication or therapy being researched and evaluated in the clinical study. Clinical studies allow researchers to gather information to determine if and how the medication works before it is available to the general population.

  • A placebo is a substance that is given in the same way as the investigational drug but does not contain any medicine. In a double-blind study like this one, the use of a placebo helps minimize bias in the results.

  • Yes. You can decide to stop at any time.